Observed reduced accelerated blood clearance of mRNA lipid nanoparticles with new hydrophilic polymers, suggesting potential for enhanced therapeutic administration.
mRNA lipid nanoparticles (LNPs) have emerged as a leading delivery system for mRNA-based vaccines and therapeutics. However, a significant limitation of this system is the presence of poly(ethylene) glycol (PEG). It is widely known that repeated doses of PEG-based therapeutics can induce an anti-PEG antibody response, leading to the accelerated blood clearance (ABC) of LNP therapeutics requiring frequent dosing, as anti-PEG antibodies have been found present in a large proportion of the population. To address this issue, we developed a mouse model for LNP clearance after a repeated dose. We then synthesised LNPs with the PEG component replaced by a library of hydrophilic polymers: poly(oligo(ethylene glycol) methyl ether methacrylate) (POEGMA), POEGMA-methacrylic acid (POEGMA (-)), POEGMA-2-(dimethylamino)ethyl methacrylate (POEGMA (+)), poly(N,N-dimethylacrylamide) (PDMA), and poly(N-(2-hydroxypropyl) methacrylamide) (PHPMA). Our results demonstrated that all three POEGMA LNPs, especially POEGMA (+) LNPs, exhibited minimal ABC effect after two weekly doses; in contrast, PDMA LNPs demonstrated significantly lower clearance in the presence of anti-PEG antibodies. This study highlights the potential of PEG-free polymer-LNPs as promising mRNA carriers that avoid rapid clearance with repeated administration.
No takes yet. Share an insight, caveat, or question.
Hassanel et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: